Dalbavancin for infective endocarditis: a single centre experience

Area of Science:

• Infectious Diseases
• Pharmacology
• Cardiology

Background:

• Infective endocarditis (IE) is a severe infection requiring prolonged antibiotic therapy, often caused by gram-positive bacteria.
• Dalbavancin, a lipoglycopeptide, exhibits potent activity against gram-positive microorganisms and possesses a unique pharmacokinetic profile.

Purpose of the Study:

• To evaluate the efficacy and safety of using dalbavancin as a completion therapy for difficult-to-treat gram-positive infective endocarditis.
• To assess dalbavancin's role in potentially shortening hospitalization for selected IE patients.

Main Methods:

• Retrospective analysis of 10 severely ill patients with difficult-to-treat IE due to gram-positive bacteria.
• Patients received dalbavancin to complete their intravenous antibiotic regimen, often after initial standard therapy.

Main Results:

• Seven out of ten patients achieved microbiological cure of IE.
• Two patients experienced IE relapse; however, no deaths were directly attributed to dalbavancin therapy.
• Short-term mortality was zero, but late mortality within one year post-discharge was 60%.

Conclusions:

• Dalbavancin can be a viable option for completing IE treatment in select patients, particularly after achieving blood culture clearance and clinical improvement.
• Its use may allow for earlier hospital discharge, but careful consideration of long-term outcomes is necessary.